108 related articles for article (PubMed ID: 21454218)
1. IgM amyloidosis: clinical features in therapeutic outcomes.
Gertz MA; Buadi FK; Hayman SR
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):146-8. PubMed ID: 21454218
[TBL] [Abstract][Full Text] [Related]
2. Transplantation for IgM amyloidosis and IgM myeloma.
Gertz MA; Hayman SR; Buadi FK
Clin Lymphoma Myeloma; 2009 Mar; 9(1):77-9. PubMed ID: 19362980
[TBL] [Abstract][Full Text] [Related]
3. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
4. Autologous stem cell transplantation and IgM amyloidosis.
Valente M; Roy V; Lacy MQ; Dispenzieri A; Gertz MA
Leuk Lymphoma; 2006 Jun; 47(6):1006-12. PubMed ID: 16840189
[TBL] [Abstract][Full Text] [Related]
5. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
[TBL] [Abstract][Full Text] [Related]
7. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal IgM-related AL amyloidosis.
Milani P; Merlini G
Best Pract Res Clin Haematol; 2016 Jun; 29(2):241-248. PubMed ID: 27825470
[TBL] [Abstract][Full Text] [Related]
9. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
10. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
11. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.
Meier-Ewert HK; Sanchorawala V; Berk J; Finn KT; Skinner M; Seldin DC; Ruberg FL
Amyloid; 2011 Jun; 18 Suppl 1():130-1. PubMed ID: 21838460
[No Abstract] [Full Text] [Related]
12. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
13. Amyloidosis with IgM monoclonal gammopathies.
Gertz MA; Kyle RA
Semin Oncol; 2003 Apr; 30(2):325-8. PubMed ID: 12720162
[TBL] [Abstract][Full Text] [Related]
14. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
15. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
[TBL] [Abstract][Full Text] [Related]
16. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Kumar SK; Dingli D; Leung N; Hogan WJ; Buadi FK; Hayman SR
Bone Marrow Transplant; 2013 Apr; 48(4):557-61. PubMed ID: 22964596
[TBL] [Abstract][Full Text] [Related]
17. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
18. Transplantation for amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar S
Curr Opin Oncol; 2007 Mar; 19(2):136-41. PubMed ID: 17272986
[TBL] [Abstract][Full Text] [Related]
19. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
20. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
